| Literature DB >> 31213516 |
Jiyun M Moon1, John A Capra1,2,3, Patrick Abbot1, Antonis Rokas4,2,3.
Abstract
Evolutionary changes in enhancers are widely associated with variation in human traits and diseases. However, studies comprehensively quantifying levels of selection on enhancers at multiple evolutionary periods during recent human evolution and how enhancer evolution varies across human tissues are lacking. To address these questions, we integrated a dataset of 41,561 transcribed enhancers active in 41 different human tissues (FANTOM Consortium) with whole genome sequences of 1,668 individuals from the African, Asian, and European populations (1000 Genomes Project). Our analyses based on four different metrics (Tajima's D, F ST, H12, nS L) showed that ∼5.90% of enhancers showed evidence of recent positive selection and that genes associated with enhancers under very recent positive selection are enriched for diverse immune-related functions. The distributions of these metrics for brain and testis enhancers were often statistically significantly different and in the direction suggestive of less positive selection compared to those of other tissues; the same was true for brain and testis enhancers that are tissue-specific compared to those that are tissue-broad and for testis enhancers associated with tissue-enriched and non-tissue-enriched genes. These differences varied considerably across metrics and tissues and were generally in the form of changes in distributions' shapes rather than shifts in their values. Collectively, these results suggest that many human enhancers experienced recent positive selection throughout multiple time periods in human evolutionary history, that this selection occurred in a tissue-dependent and immune-related functional context, and that much like the evolution of their protein-coding gene counterparts, the evolution of brain and testis enhancers has been markedly different from that of enhancers in other tissues.Entities:
Keywords: brain; enhancers; human evolution; immunity; recent positive selection; testis
Mesh:
Substances:
Year: 2019 PMID: 31213516 PMCID: PMC6686946 DOI: 10.1534/g3.119.400186
Source DB: PubMed Journal: G3 (Bethesda) ISSN: 2160-1836 Impact factor: 3.154
Figure 1Visual summary of the FANTOM5 enhancer data set used in this study Each circle represents a tissue and all 41 tissues are grouped into non-overlapping organ systems and are color-coded accordingly. The size of the circle is proportional to the log10 of the number of enhancers active within each tissue (Table S1: from highest to lowest: brain: 4,883, blood: 3,657, spleen: 2,429, lung: 2,366, thymus: 1,741, heart: 1,737, testis: 1,621, meninx: 1,447, kidney: 1,294, large-intestine: 1,266, tonsil: 1,193, adipose-tissue: 1,161, spinal-cord: 1,115, eye: 1,019, blood-vessel: 982, small-intestine: 880, uterus: 877, liver: 875, internal-male-genitalia: 846, esophagus: 845, thyroid-gland: 795, skeletal-muscle: 784, throat: 782, placenta: 735, tongue: 708, female-gonad: 693, prostate-gland: 667, gallbladder: 654, urinary-bladder: 602, vagina: 512, salivary-gland: 387, olfactory-region: 338, lymph-node: 292, smooth-muscle: 270, pancreas: 243, parotid-gland: 184, skin: 161, submandibular-gland: 159, penis: 154, umbilical-cord: 115, stomach: 92).
Figure 2Proportions of enhancers exhibiting significant deviations from neutral expectations for different recent positive selection metrics across 41 tissues Each dot represents the proportion of enhancers (Y-axis) that exhibited significant deviation from the neutral model (i.e., p-value < 0.05) in a given tissue (X-axis). Differently colored dots correspond to the different selection metrics used (Salmon: Tajima’s D; Teal: FST; Green: H12; Blue Gray: nSL (Africans); Orange: nSL (Europeans); Purple: nSL (East Asians)). For each metric, the p-value for the observed value for an enhancer (i.e., the likelihood under neutral expectations of obtaining a value as or more extreme as the observed value) was assessed by comparing to 10,000 simulated values calculated on sequences generated from the neutral simulations. Differently colored horizontal lines correspond to the average of all proportions calculated for all 41 tissues according to the different selection metrics used (Salmon: Tajima’s D; Teal: FST; Green: H12; Blue Gray: nSL (Africans); Orange: nSL (Europeans); Purple: nSL (East Asians)). Note the 1) differences in the proportion of enhancers exhibiting significant deviations from neutral expectations across tissues in any given metric, and 2) similarly, differences in the proportion of enhancers with significant deviations from the neutral model across all metrics in any given tissue.
Number of tissues with one or more significantly enriched GO Terms
| Metric | # of Biological Process GO terms | # of Molecular Function GO terms | # of Cellular Compartment GO terms |
|---|---|---|---|
| Tajima’s | 4 | 2 | 4 |
| 2 | 2 | 2 | |
| H12 | 0 | 1 | 1 |
| 18 | 18 | 18 | |
| 20 | 20 | 19 | |
| 19 | 19 | 19 |
Most frequently-occurring GO terms among enhancers with evidence of recent positive selection by nSL across tissues in Africans
| BP GO Terms | # of tissues | MF Go Terms | # of tissues | CC GO Terms | # of tissues |
|---|---|---|---|---|---|
| Antigen processing and presentation of exogenous peptide antigen | 18 | MHC class II receptor activity | 18 | 18 | |
| T cell co-stimulation | 18 | MHC class II protein complex binding | 18 | Integral component of luminal side of endoplasmic reticulum membrane | 18 |
| Interferon-gamma-mediated signaling pathway | 17 | Peptide antigen binding | 15 | Endosome membrane | 18 |
| T cell receptor signaling pathway | 16 | TAP1 binding | 13 | ER to Golgi transport vesicle membrane | 17 |
| Antigen processing and presentation of exogenous peptide antigen via MHC class I TAP dependent | 15 | Peptide antigen-transporting ATPase activity | 12 | Lysosomal membrane | 16 |
| MHC class II protein complex assembly | 14 | TAP2-binding | 10 | TAP complex | 14 |
| MHC protein complex | 11 |
Most frequently-occurring GO terms among enhancers with evidence of recent positive selection by nSL across tissues in Europeans
| BP GO Terms | # of tissues | MF GO Terms | # of tissues | CC GO Terms | # of tissues |
|---|---|---|---|---|---|
| Interferon gamma-mediated signaling pathway | 18 | MHC class II receptor activity | 18 | Integral component of luminal side of endoplasmic reticulum membrane | 19 |
| Antigen processing and presentation of exogenous peptide antigen | 17 | MHC class II protein complex binding | 18 | ER to Golgi transport vesicle membrane | 18 |
| T cell co-stimulation | 17 | Peptide antigen binding | 15 | 18 | |
| T cell receptor signaling pathway | 14 | TAP1 binding | 14 | Endosome membrane | 17 |
| MHC class II protein complex assembly | 13 | Lysosomal membrane | 15 | ||
| Endocytic vesicle membrane | 12 | ||||
| TAP complex | 12 | ||||
| MHC protein complex | 12 |
Most frequently-occurring GO terms among enhancers with evidence of recent positive selection by nSL across tissues in East Asians
| BP GO Terms | # of tissues | MF GO Terms | # of tissues | CC GO Terms | # of tissues |
|---|---|---|---|---|---|
| Antigen processing and presentation of exogenous peptide antigen | 17 | Peptide antigen binding | 19 | Integral component of luminal side of endoplasmic reticulum membrane | 19 |
| T cell co-stimulation | 17 | MHC class II receptor activity | 18 | 18 | |
| interferon-gamma-mediated signaling pathway | 16 | MHC class II protein complex binding | 18 | Lysosomal membrane | 18 |
| T cell receptor signaling pathway | 15 | TAP1 binding | 12 | ER to Golgi transport vesicle membrane | 17 |
| MHC class II protein complex assembly | 14 | Endocytic vesicle membrane | 16 | ||
| Antigen processing and presentation of exogenous peptide antigen via MHC class I TAP dependent | 11 | TAP complex | 12 | ||
| Endosome membrane | 10 | ||||
| MHC II protein complex | 10 |
Figure 3Pairwise comparisons of the patterns of recent evolution among enhancers from 41 tissues Each graph shows the results of the pairwise Kolmogorov-Smirnov tests carried out between all pairs of 41 tissues (shown on the X- and Y-axes) for all recent positive selection metrics. Each cell represents a pairwise comparison between two specific tissues: red-filled cells represent pairwise comparisons that are statistically significant (i.e., adjusted p-value < 0.05) and empty cells represent non-significant pairwise comparisons.
Figure 4Comparisons of patterns of recent evolution between tissue-specific and tissue-broad enhancers (a) The grid panel depicts which tissues exhibit significantly different distributions of metrics between tissue-specific and tissue-broad enhancers. Each cell represents a comparison between tissue-specific and tissue-broad enhancers in a given tissue: pink-filled cells represent the comparisons that are statistically significant (i.e., adjusted p-value < 0.05) and empty cells represent non-significant comparisons. (b–d) Violin plots depicting the distributions of the metrics for tissue-specific and tissue-broad enhancers for brain and testis for (b) Tajima’s D, (c) Weir & Cockerham’s FST, and (d) H12. In all cases, the distributions of tissue-specific and tissue-broad enhancers were significantly different (see also panel a).
Figure 5Comparisons of patterns of recent evolution between enhancers associated with tissue-enriched genes and enhancers associated with non-tissue-enriched genes in brain and testis The violin plots depicting the distributions of the metrics for enhancers associated with tissue-enriched and non-tissue-enriched genes for brain and testis for: (a) Tajima’s D (b) Weir & Cockerham’s FST (c) H12 (d) nSL (Africans) (e) nSL (Europeans) (f) nSL (East Asians). Plots with asterisks above them indicate significant pairwise comparisons.
Complex human traits and diseases associated with variants within the brain enhancers that exhibit evidence of recent selection
| Enhancer ID | rsID | Traits | Metrics |
|---|---|---|---|
| chr2:219271996-219272374 | rs921968 | Mean corpuscular hemoglobin concentration | |
| chr3:181418145-181418802 | rs34308817 | Ankle injury | Tajima’s |
| chr6:30069810-30070038 | rs1111180 | Eosinophil percentage of granulocytes, Eosinophil percentage of white cells | |
| chr6:30923441-30923743 | rs17189763 | Conotruncal heart defects (maternal effects) | |
| chr6:32427743-32428120 | rs9268831 | Response to hepatitis B vaccine | |
| chr6:32427743-32428120 | rs9268835 | Type 2 diabetes | |
| chr6:32577297-32577935 | rs660895 | IgA nephropathy, Rheumatoid arthritis, Rheumatoid arthritis (ACPA-negative) | |
| chr7:130720133-130720826 | rs10265693 | Lung cancer | |
| chr7:29217860-29218383 | rs245914 | Psychosis (atypical), Obesity-related traits | Tajima’s |
| chr13:110790027-110791241 | rs641862 | Obesity-related traits | Tajima’s |
| chr16:22201170-22202123 | rs145049847 | Alzheimer disease and age of onset | Tajima’s |
| chr16:87856343-87856555 | rs76069656 | Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes | |
| chr16:87886258-87886670 | rs68149176 | Mean corpuscular volume, Mean corpuscular hemoglobin | |
| chr21:45616099-45616530 | rs4456788 | Chronic inflammatory diseases (ankylosing spondylitis, Crohn’s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) |
Complex human traits and diseases associated with variants within the testis enhancers that exhibit evidence of recent selection
| Enhancer ID | rsID | Traits | Metrics |
|---|---|---|---|
| Chr6:30069810-30070038 | rs1111180 | Eosinophil percentage of granulocytes, Eosinophil percentage of white cells | |
| Chr6:30923441-30923743 | rs17189763 | Conotruncal heart defects (maternal effects) |